Siouxland agency not expecting LIHEAP to be affected by federal cuts
SIOUX CITY, Iowa (KCAU) — An energy assistance program will not be impacted by federal cuts, according to the local organization that carries it out.
Staffing cuts at the Department of Health and Human Services included federal workers overseeing the Low Income Home Energy Assistance Program (LIHEAP). The Community Action Agency of Siouxland's executive director Jean Logan spoke with representatives about the potential impacts the federal staff layoff could have.
Sioux City receives $500K grant for wastewater treatment improvements
Logan told KCAU 9 that the program at the local level will not see an impact. That's because 90 percent of the funds have already been sent to the states. However, there are some questions regarding the remaining funds.
'It's anticipated that the last 10 percent is going to be delayed, but still received by the states,' Logan said. 'I also heard today that if that funding is held up, we'll still be able to take applications and hopefully get applications paid in a timely manner.'
About 2,700 Siouxland families have received assistance through the program this past winter. Logan says there is still time to apply for LIHEAP, as the program runs through April 30. Siouxlanders can apply by appointment or on the agency's website — click here for more information.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
No drug price pledges in talks with US government, Pfizer CEO says
STORY: Pfizer CEO Albert Bourla said Monday that he and other drug companies met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made. He made the comments at a Goldman Sachs healthcare conference. Last month President Trump issued an executive order directing drugmakers to lower the prices of their medicines to align with what other countries pay. According to the order, the administration was to set "Most Favored Nation" price targets within 30 days. The Department of Health and Human Services has said it expects drugmakers in the U.S. to set prices for their products at the lowest price paid by other high-income countries. Bourla said he didn't know what the companies would hear in 30 days and added the meetings with the administration so far were cordial but (quote) "not digging into the substance." It is unclear what mechanism the U.S. government will use to lower drug prices - analysts and legal experts have said the policy will be difficult to implement. Bourla said he is hopeful that, given U.S. pressure on European countries to pay more, prices there could increase. He said that if the U.S. resorts to price controls, Pfizer could consider not making drugs available for government reimbursement in some countries if prices don't increase there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Yahoo
No drug price pledges in talks with US government, Pfizer CEO says
STORY: Pfizer CEO Albert Bourla said Monday that he and other drug companies met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made. He made the comments at a Goldman Sachs healthcare conference. Last month President Trump issued an executive order directing drugmakers to lower the prices of their medicines to align with what other countries pay. According to the order, the administration was to set "Most Favored Nation" price targets within 30 days. The Department of Health and Human Services has said it expects drugmakers in the U.S. to set prices for their products at the lowest price paid by other high-income countries. Bourla said he didn't know what the companies would hear in 30 days and added the meetings with the administration so far were cordial but (quote) "not digging into the substance." It is unclear what mechanism the U.S. government will use to lower drug prices - analysts and legal experts have said the policy will be difficult to implement. Bourla said he is hopeful that, given U.S. pressure on European countries to pay more, prices there could increase. He said that if the U.S. resorts to price controls, Pfizer could consider not making drugs available for government reimbursement in some countries if prices don't increase there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Epoch Times
20 hours ago
- Epoch Times
RFK Jr. Says Analyst Working to Find Lost Vaccine Safety Data
A researcher hired this year by the Department of Health and Human Services (HHS) is working with other scientists to recover data missing from a vaccine safety system, Health Secretary Robert F. Kennedy Jr. said on June 7. David Geier, the researcher, is working on recovering Vaccine Safety Datalink (VSD) data that the Centers for Disease Control and Prevention has said are missing, Kennedy